Comparative Pharmacology
Head-to-head clinical analysis: CIPRO versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPRO versus LEVOFLOXACIN IN DEXTROSE 5 IN PLASTIC CONTAINER.
CIPRO vs LEVOFLOXACIN IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, preventing DNA replication and transcription, leading to bacterial cell death.
Levofloxacin is a fluoroquinolone antibiotic that inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, thereby inhibiting DNA replication and transcription.
Ciprofloxacin 500 mg PO q12h or 400 mg IV q12h for uncomplicated infections; 750 mg PO q12h or 400 mg IV q8h for severe/complicated infections.
500 mg or 750 mg intravenously once daily. Infusion over 60-90 minutes.
None Documented
None Documented
Terminal elimination half-life: 3-5 hours (normal renal function), extended to 8-10 hours in mild-to-moderate renal impairment (CrCl 30-50 mL/min) and up to >10 hours in severe impairment (CrCl <30 mL/min); half-life in elderly may be 5-8 hours due to reduced clearance.
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
6-8 hours in patients with normal renal function (creatinine clearance >50 mL/min); increases to 20-48 hours in severe renal impairment (CrCl <20 mL/min); clinically relevant for dosing interval adjustment.
Renal (50-70% unchanged via glomerular filtration and tubular secretion); biliary/fecal (15-20%, primarily as metabolites); small amount metabolized to 4 metabolites (oxo-, sulfo-, and desethylene-ciprofloxacin).
Renal: ~87% of dose excreted unchanged in urine via glomerular filtration and tubular secretion; biliary/fecal: <5% eliminated as unchanged drug and metabolites; <4% recovered in feces.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic